The domestic prescription drug market is not a market where prices can operate with competitiveness. This is because paying patients do not have the option to choose a product, and doctors who have the option do not have a margin on sales of insurance drugs, so there is little incentive to prescribe low-priced products. Because of this, even generics that sell products with the same ingredients want a higher insurance limit.

However, in the product market where treatment costs are high and the number of products is small, price competition sometimes takes place. A good example is Lucentis biosimilar, a treatment for macular degeneration. Only two companies, Chong Kun Dang and Samsung Bioepis, entered t